$AVBP News

Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43

ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies

ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate

ArriVent BioPharma: A First Assessment

Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026

ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting

BTIG Assumes ArriVent BioPharma at Buy, Announces Price Target of $42

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Oppenheimer Reiterates Outperform on ArriVent BioPharma, Raises Price Target to $50

Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $33

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $44